Covid19 — BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST)
Citation(s)
Aaby P, Benn CS Saving lives by training innate immunity with bacille Calmette-Guerin vaccine. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17317-8. doi: 10.1073/pnas.1215761109. Epub 2012 Oct 15.
Akiyama, Y and T. Ishida, Relationship between COVID-19 death toll doubling time and national BCG vaccination policy. medRxiv, 2020: p. 2020.04.06.20055251.
Alunno A, Carubbi F, Rodríguez-Carrio J Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin. RMD Open. 2020 May;6(1). pii: e001295. doi: 10.1136/rmdopen-2020-001295.
Anderson FD, Ushijima RN, Larson CL Recurrent herpes genitalis. Treatment with Mycobacterium bovis (BCG). Obstet Gynecol. 1974 Jun;43(6):797-805.
Behr MA, Small PM A historical and molecular phylogeny of BCG strains. Vaccine. 1999 Feb 26;17(7-8):915-22.
Berg MK, Yu Q, Salvador CE, Melani I, Kitayama S Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19. Sci Adv. 2020 Aug 5;6(32):eabc1463. doi: 10.1126/sciadv.abc1463. eCollection 2020 Aug.
Calmette A Preventive Vaccination Against Tuberculosis with BCG. Proc R Soc Med. 1931 Sep;24(11):1481-90.
Calmette, A G., C.; Weill-Halle, B., Essai d'immunisation contre l'infection tuberculeuse. Bull Acad Med Paris, 1924(91): p. 787-796.
Cao J, Tu WJ, Cheng W, Yu L, Liu YK, Hu X, Liu Q Clinical Features and Short-term Outcomes of 102 Patients with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020 Jul 28;71(15):748-755. doi: 10.1093/cid/ciaa243.
Chen JM, Islam ST, Ren H, Liu J Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety. Vaccine. 2007 Nov 23;25(48):8114-22. Epub 2007 Oct 8.
Civil RH, Warren KS, Mahmoud AA Conditions for bacille Calmette-Guérin-induced resistance to infection with Schistosoma mansoni in mice. J Infect Dis. 1978 May;137(5):550-5.
Clark IA, Allison AC, Cox FE Protection of mice against Babesia and Plasmodium with BCG. Nature. 1976 Jan 29;259(5541):309-11.
Collaborative, T O. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv, 2020.
Danzi GB, Loffi M, Galeazzi G, Gherbesi E Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020 May 14;41(19):1858. doi: 10.1093/eurheartj/ehaa254.
Daulatabad D, Pandhi D, Singal A BCG vaccine for immunotherapy in warts: is it really safe in a tuberculosis endemic area? Dermatol Ther. 2016 May;29(3):168-72. doi: 10.1111/dth.12336. Epub 2016 Jan 26.
de Castro MJ, Pardo-Seco J, Martinón-Torres F Nonspecific (Heterologous) Protection of Neonatal BCG Vaccination Against Hospitalization Due to Respiratory Infection and Sepsis. Clin Infect Dis. 2015 Jun 1;60(11):1611-9. doi: 10.1093/cid/civ144. Epub 2015 Feb 27.
DUBOS RJ, SCHAEDLER RW Effects of cellular constituents of mycobacteria on the resistance of mice to heterologous infections I. Protective effects. J Exp Med. 1957 Nov 1;106(5):703-17.
Escobar LE, Molina-Cruz A, Barillas-Mury C BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17720-17726. doi: 10.1073/pnas.2008410117. Epub 2020 Jul 9. Erratum in: Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27741-27742.
Fine PE Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995 Nov 18;346(8986):1339-45. Review. Erratum in: Lancet 1996 Feb 3;347(8997):340.
Floc'h F, Werner GH Increased resistance to virus infections of mice inoculated with BCG (Bacillus calmette-guérin). Ann Immunol (Paris). 1976 Mar-Apr;127(2):173-86.
Gallagher, J , C. Watson, and M. Ledwidge, Association of Bacille Calmette-Guérin (BCG), Adult Pneumococcal and Adult Seasonal Influenza Vaccines with Covid-19 Adjusted Mortality Rates in Level 4 European countries. medRxiv, 2020: p. 2020.06.03.20121624.
Guérin N, Teulières L, Noba A, Schlumberger M, Bregère P, Chauvin P Comparison of the safety and immunogenicity of the lyophilized Mérieux seed and the World Health Organization working reference BCG vaccines in school-aged children in Senegal. Vaccine. 1999 Jan;17(2):105-9.
Hippmann G, Wekkeli M, Rosenkranz AR, Jarisch R, Götz M [Nonspecific immune stimulation with BCG in Herpes simplex recidivans. Follow-up 5 to 10 years after BCG vaccination]. Wien Klin Wochenschr. 1992;104(7):200-4. German.
Hoff R Killing in vitro of Trypanosoma cruzi by macrophages from mice immunized with T. cruzi or BCG, and absence of cross-immunity on challege in vivo. J Exp Med. 1975 Aug 1;142(2):299-311.
Hollm-Delgado MG, Stuart EA, Black RE Acute lower respiratory infection among Bacille Calmette-Guérin (BCG)-vaccinated children. Pediatrics. 2014 Jan;133(1):e73-81. doi: 10.1542/peds.2013-2218. Epub 2013 Dec 30.
Houchens DP, Goldberg AI, Gaston MR, Kende M, Goldin A Studies of the effects of Bacillus Calmette-Guérin on Moloney sarcoma virus-induced tumors in normal and immunosuppressed mice. Cancer Res. 1973 Apr;33(4):685-90.
HOWARD JG, BIOZZI G, HALPERN BN, STIFFEL C, MOUTON D The effect of Mycobacterium tuberculosis (BCG) infection on the resistance of mice to bacterial endotoxin and Salmonella enteritidis infection. Br J Exp Pathol. 1959 Jun;40(3):281-90.
Klinger D, Blass I, Rappoport N, Linial M Significantly Improved COVID-19 Outcomes in Countries with Higher BCG Vaccination Coverage: A Multivariable Analysis. Vaccines (Basel). 2020 Jul 11;8(3). pii: E378. doi: 10.3390/vaccines8030378.
Larson CL, Ushijima RN, Karim R, Baker MB, Baker RE Herpesvirus hominis type 2 infections in rabbits: effect of prior immunization with attenuated Mycobacterium bovis (BCG) cells. Infect Immun. 1972 Oct;6(4):465-8.
LEMONDE P, CLODE M Effect of BCG infection on leukemia and polyoma in mice and hamsters. Proc Soc Exp Biol Med. 1962 Dec;111:739-42.
Lind A The Swedish strain of BCG. Tubercle. 1983 Sep;64(3):223-4.
Liu J, Tran V, Leung AS, Alexander DC, Zhu B BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccin. 2009 Feb;5(2):70-8. Epub 2009 Feb 20. Review.
Onder G, Rezza G, Brusaferro S Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020 May 12;323(18):1775-1776. doi: 10.1001/jama.2020.4683. Erratum in: JAMA. 2020 Apr 28;323(16):1619.
Ortiz-Ortiz L, Gonzalez-Mendoza A, Lamoyi E A vaccination procedure against Trypanosoma cruzi infection in mice by nonspecific immunization. J Immunol. 1975 Apr;114(4):1424-5.
Sakula A BCG: who were Calmette and Guérin? Thorax. 1983 Nov;38(11):806-12.
Sakuma T, Suenaga T, Yoshida I, Azuma M Mechanisms of enhanced resistance of Mycobacterium bovis BCG-treated mice to ectromelia virus infection. Infect Immun. 1983 Nov;42(2):567-73.
Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients. AJR Am J Roentgenol. 2020 Jul;215(1):87-93. doi: 10.2214/AJR.20.23034. Epub 2020 Mar 14.
Salem A, Nofal A, Hosny D Treatment of common and plane warts in children with topical viable Bacillus Calmette-Guerin. Pediatr Dermatol. 2013 Jan-Feb;30(1):60-3. doi: 10.1111/j.1525-1470.2012.01848.x. Epub 2012 Sep 7.
Shann F Nonspecific effects of vaccines and the reduction of mortality in children. Clin Ther. 2013 Feb;35(2):109-14. doi: 10.1016/j.clinthera.2013.01.007. Epub 2013 Jan 31. Review.
Shann F The non-specific effects of vaccines. Arch Dis Child. 2010 Sep;95(9):662-7. doi: 10.1136/adc.2009.157537. Review.
Sher NA, Chaparas SD, Greenberg LE, Bernard S Effects of BCG, Corynebacterium parvum, and methanol-extration residue in the reduction of mortality from Staphylococcus aureus and Candida albicans infections in immunosuppressed mice. Infect Immun. 1975 Dec;12(6):1325-30.
Smith, K C., I.M. Orme, and J.R. Starke, 35 - Tuberculosis vaccines, in Vaccines (Sixth Edition), S.A. Plotkin, W.A. Orenstein, and P.A. Offit, Editors. 2013, W.B. Saunders: London. p. 789-811.
Smrkovski LL, Larson CL Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice. Infect Immun. 1977 Apr;16(1):249-57.
Spencer JC, Ganguly R, Waldman RH Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guérin. J Infect Dis. 1977 Aug;136(2):171-5.
Starr SE, Visintine AM, Tomeh MO, Nahmias AJ Effects of immunostimulants on resistance of newborn mice to herpes simplex type 2 infection. Proc Soc Exp Biol Med. 1976 May;152(1):57-60.
Suenaga T, Okuyama T, Yoshida I, Azuma M Effect of Mycobacterium tuberculosis BCG infection on the resistance of mice to ectromelia virus infection: participation of interferon in enhanced resistance. Infect Immun. 1978 Apr;20(1):312-4.
van 't Wout JW, Poell R, van Furth R The role of BCG/PPD-activated macrophages in resistance against systemic candidiasis in mice. Scand J Immunol. 1992 Nov;36(5):713-9.
WALLGREN, A , INTRADERMAL VACCINATIONS WITH B C G VIRUS: PRELIMINARY NOTE. Journal of the American Medical Association, 1928. 91(24): p. 1876-1881.
Wardhana, Datau EA, Sultana A, Mandang VV, Jim E The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med Indones. 2011 Jul;43(3):185-90.
Werner GT The effect of BCG-vaccination on vaccinia virus infections in mice. Experientia. 1979 Nov 15;35(11):1514-5.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.